Abbott is acquiring portfolio of contrast agentsAre you ready for a new player in the U.S. contrast agent market?Abbott Laboratories gained instant stature in the industry lastmonth when it signed an alliance with Berlex Laboratories, theU.S.
Are you ready for a new player in the U.S. contrast agent market?Abbott Laboratories gained instant stature in the industry lastmonth when it signed an alliance with Berlex Laboratories, theU.S. subsidiary of German contrast giant Schering.
Under the terms of the deal, Abbott on July 1 began marketingSchering's Magnevist MRI agent and Ultravist x-ray agent to hospitals,with technical support from Berlex sales representatives. Magnevistwas the first MRI contrast agent on the U.S. market and stillmaintains the largest market share, while Berlex introduced Ultravistto the U.S. market last year (SCAN 6/7/95). The products are theonly imaging agents marketed in the U.S. by Berlex, which hadU.S. sales of $525 million last year.
The deal is the latest in a series of moves Abbott has made asit builds a position in the imaging industry. The Abbott Park,IL, company in May acquired U.S. marketing rights to EchoGen,an ultrasound contrast agent being developed by Sonus Pharmaceuticals(SCAN 5/22/96). Abbott has also filed an abbreviated new drugapplication for a generic version of Bracco's iopamidol nonionicx-ray agent, although Abbott remains mum on its intentions inthe generic segment.
Abbott is interested in broadening its product offerings to customers,and the Berlex agreement gives it instant access to an imagingagent product line, according to spokesperson Laureen Cassidy.
"It is a new business opportunity," Cassidy said.
"Abbott is very interested in its relationships with varioushealthcare systems, in terms of a breadth of products."
Berlex, on the other hand, will benefit by having its productsmarketed by Abbott's large sales force, which calls on thousandsof hospitals, according to Berlex spokesperson Wendy Neininger.Abbott sells a wide range of devices and consumables, includinganesthesia, drug delivery systems, IV solutions, oncology therapydrugs, and pumps.
Abbott will handle contracting for Magnevist and Ultravist, suchas negotiating the terms of sales agreements, signing contracts,shipping and distributing products, conducting support services,and other customer service functions. Berlex will provide technicalsupport, including product positioning and helping radiologists,referring physicians, and hospital executives understand the roleof contrast in medical imaging, according to Neininger.
"Berlex will maintain its presence in the hospital environment,but in a very specific role," she said.
Berlex will maintain responsibility for selling Magnevist andUltravist to the freestanding imaging center market. Berlex willalso continue to manufacture both products.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.